Results 31 to 40 of about 743,614 (307)
BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD. [PDF]
, 2018 BACKGROUND AND OBJECTIVES: In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive systolic BP treatment (target
Dias, C +4 more
core +1 more source
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Journal of Diabetes Investigation, 2022 Cardiovascular (CV) disease is the most alarming complication of diabetes mellitus (DM), and a strategy aiming at cardiovascular event prevention in diabetes mellitus has long been debated.
Hiroaki Yagyu, Hitoshi Shimano
doaj +1 more source
Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
Pharmacology of cardiovascular chronotherapeutic agents [PDF]
American Journal of Hypertension, 2001 Although sudden cardiac death, myocardial infarction, or stroke can occur at any time of day, event rates increase during the waking hours, particularly in the morning. In most people-both normotensive and hypertensive-blood pressure (BP) rises rapidly in the early morning hours, the time when most individuals wake and begin their day.
openaire +2 more sources
Motivational Interviewing Impact on Cardiovascular Disease [PDF]
, 2020 : Harm reduction in cardiovascular disease is a significant problem worldwide. Providers, families, and healthcare agencies are feeling the burdens imparted by these diseases.
core
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [PDF]
, 2016 Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes
Bergenstal, RM +15 more
core +1 more source
Journal of Cardiovascular Development and Disease, 2022 Ischemic cardiovascular diseases have a high incidence and high mortality worldwide. Therapeutic advances in the last decades have reduced cardiovascular mortality, with antithrombotic therapy being the cornerstone of medical treatment.
Ignacio Barriuso +2 more
doaj +1 more source
New antiplatelet agents for cardiovascular disease [PDF]
Canadian Medical Association Journal, 2013 Antiplatelet therapy is a key component in the management of many medical diseases to decrease the risk of cardiovascular events.[1][1] Acetylsalicyclic acid (ASA) is the most common antiplatelet agent used and is usually first-line therapy. Use of clopidogrel, especially in combination with ASA,
Doson, Chua, Cesilia, Nishi
openaire +2 more sources
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley +1 more source
Cardiovascular Diabetology, 2019 Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 diabetes mellitus (T2DM).
Salvatore Carbone, Dave L. Dixon
doaj +1 more source